CD274 and neoplasm: The 22C3 assay uses a combined positive score (CPS) based on both tumor cells and immune cells (lymphocytes and macrophages) staining to determine PD-L1-positive tumors in mTNBC patients for pembrolizumab, with a cutoff value of 10 in KEYNOTE-355.